Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfamethazine is a synthetic sulfonamide antibacterial agent used primarily in veterinary medicine and previously in human medicine for the treatment of various bacterial infections. It acts as a bacteriostatic agent by inhibiting the enzyme dihydropteroate synthase, thereby blocking the synthesis of dihydrofolic acid from para-aminobenzoic acid (PABA), which is essential for bacterial DNA and nucleotide synthesis. Sulfamethazine has been used to treat respiratory diseases and promote growth in food-producing animals such as cattle, sheep, pigs, and poultry. Its spectrum of activity is similar to other sulfonamides[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethazine.